{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:07Z","timestamp":1787026567665,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Autologous hematopoietic stem cell transplantation (AHSCT) is an effective treatment for relapsing remitting multiple sclerosis, yet the mechanisms underlying immune reset and sustained remission remain incompletely understood. This study provides a longitudinal immune profiling of patients undergoing AHSCT, with a specific focus on immune reconstitution at two years post-AHSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Peripheral blood mononuclear cells (PBMCs) were collected from 22 relapsing-remitting multiple sclerosis patients at baseline and multiple time points post-AHSCT. Immune reconstitution was characterized using high-dimensional mass cytometry (CyTOF) and flow cytometry to assess phenotypic changes in B cells, T cells, and myeloid cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      AHSCT led to profound alterations in immune cell populations. B-cell recovery was marked by a rapid expansion of na\u00efve B cells, while memory B cells and plasmablasts remained depleted. Notably, patients with evidence of inflammatory disease activity (EIDA) post-AHSCT exhibited higher pre-transplant frequencies of non-switched IgD\n                      <jats:sup>+<\/jats:sup>\n                      IgM\n                      <jats:sup>+<\/jats:sup>\n                      memory B cells, raising the possibility of a potential biomarker for treatment response. Myeloid-cell reconstitution showed a decline in classical monocytes and an increase in non-classical monocytes and plasmacytoid dendritic cells, potentially shifting the immune balance toward a more tolerogenic state. CD4 T-cell reconstitution demonstrated a shift from central memory (T\n                      <jats:sub>cm<\/jats:sub>\n                      ) to effector memory (T\n                      <jats:sub>em<\/jats:sub>\n                      ) phenotypes, with a selective depletion of polyfunctional Th1\/Th17cells lacking PD-1 expression. Clusters enriched for PD-1\n                      <jats:sup>+<\/jats:sup>\n                      T\n                      <jats:sub>em<\/jats:sub>\n                      CD4 T cells appeared to differ between patients with and without EIDA. Furthermore, an increase in atypical na\u00efve CCR7\n                      <jats:sup>\u207b<\/jats:sup>\n                      CD62L\n                      <jats:sup>\u207b<\/jats:sup>\n                      CD4 T cells was observed in EIDA patients, raising questions about their role in the pathophysiology of MS. CD8 T-cell reconstitution followed a similar pattern, with a shift from a na\u00efve\/T\n                      <jats:sub>cm<\/jats:sub>\n                      -dominant to a T\n                      <jats:sub>em<\/jats:sub>\n                      -skewed population, albeit with substantial interpatient variability. Mucosal-associated invariant T cells (MAIT) cells showed a sustained decrease, possibly reflecting microbiota alterations post-transplant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, these findings provide an exploratory characterization of immune reconstitution following AHSCT, highlighting candidate biomarkers and mechanisms that warrant validation in larger cohorts to guide patient stratification and monitor treatment responses in multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1601223","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:30:30Z","timestamp":1751283030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal immune profiling following autologous hematopoietic stem cell transplantation in multiple sclerosis: insights into immune reconstitution and disease modulation"],"prefix":"10.3389","volume":"16","author":[{"given":"Malin","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127655","article-title":"Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis","volume":"5","author":"Harris","year":"2020","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.782935","article-title":"Long-term suppression of circulating proinflammatory cytokines in multiple sclerosis patients following autologous haematopoietic stem cell transplantation","volume":"12","author":"Hendrawan","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00834","article-title":"Natural killer cells regulate th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis","volume":"9","author":"Darlington","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51510","article-title":"Sustained immunotolerance in multiple sclerosis after stem cell transplant","volume":"9","author":"Visweswaran","year":"2022","journal-title":"Ann Clin Trans neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12985","article-title":"Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation","volume":"189","author":"Karnell","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"109709","DOI":"10.1016\/j.clim.2023.109709","article-title":"Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis","volume":"254","author":"Massey","year":"2023","journal-title":"Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)62388-4","article-title":"Immune reconstitution after autologous hematopoietic stem cell transplantation","volume":"76","author":"Porrata","year":"2001","journal-title":"Mayo Clinic Proc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200027","article-title":"B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"9","author":"von Niederhausern","year":"2022","journal-title":"Neurology(R) neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00121","article-title":"An exponential regression model reveals the continuous development of B cell subpopulations used as reference values in children","volume":"6","author":"Konigs","year":"2018","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1308378","article-title":"Human IgM-expressing memory B cells","volume":"14","author":"Budeus","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv473","article-title":"MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes","volume":"25","author":"Comabella","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.90.15_supplement.P3.397","article-title":"Efficacy and safety of tabalumab in patients with relapsing\u2013remitting multiple sclerosis: a randomized, double-blind, placebo-controlled study","volume":"90","author":"Silk","year":"2018","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00642","article-title":"B cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions","volume":"6","author":"Claes","year":"2015","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676686","article-title":"Memory B cells in multiple sclerosis: emerging players in disease pathogenesis","volume":"12","author":"DiSano","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-335512","article-title":"Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis","author":"Noui","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.110","article-title":"Myeloid cells - targets of medication in multiple sclerosis","volume":"12","author":"Mishra","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx113","article-title":"Loss of \u2018homeostatic\u2019 microglia and patterns of their activation in active multiple sclerosis","volume":"140","author":"Zrzavy","year":"2017","journal-title":"Brain"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02035","article-title":"Human monocyte subsets and phenotypes in major chronic inflammatory diseases","volume":"10","author":"Kapellos","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Consortium","year":"2011","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1579739","article-title":"Immunology of multiple sclerosis","volume":"36","author":"Sospedra","year":"2016","journal-title":"Semin Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01068","article-title":"L-selectin: A major regulator of leukocyte adhesion, migration and signaling","volume":"10","author":"Ivetic","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073833","article-title":"Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse","volume":"67","author":"Burgoyne","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/08916930701391579","article-title":"Quantitation of peripheral blood markers of rat experimental autoimmune encephalomyelitis","volume":"40","author":"Izmailova","year":"2007","journal-title":"Autoimmunity"},{"key":"B35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.msard.2018.12.019","article-title":"The proportion of peripheral regulatory T cells in patients with Multiple Sclerosis: A meta-analysis","volume":"28","author":"Li","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.08.010","article-title":"Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant","volume":"25","author":"Massey","year":"2023","journal-title":"Cytotherapy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2153534","DOI":"10.1080\/21645515.2022.2153534","article-title":"Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers","volume":"18","author":"Verreycken","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt182","article-title":"Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis","volume":"136","author":"Abrahamsson","year":"2013","journal-title":"Brain"},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-323-90242-7.00003-1","article-title":"Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"202","author":"Mariottini","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/imm.2013.140.issue-2","article-title":"T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis","volume":"140","author":"Burman","year":"2013","journal-title":"Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2016.03.004","article-title":"Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"64","author":"Arruda","year":"2016","journal-title":"Curr Res Transl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1467-x","article-title":"Opposing T cell responses in experimental autoimmune encephalomyelitis","volume":"572","author":"Saligrama","year":"2019","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.12.7579","article-title":"Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL\/6 mice","volume":"166","author":"Sun","year":"2001","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.10.2237.2237","article-title":"A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis","volume":"77","author":"Autran","year":"1991","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0444-8","article-title":"The biology and functional importance of MAIT cells","volume":"20","author":"Godfrey","year":"2019","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2016.03.014","article-title":"Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis","author":"Salou","year":"2016","journal-title":"Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344160","article-title":"CD8(+) MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis","volume":"44","author":"Willing","year":"2014","journal-title":"Eur J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.794077","article-title":"NK cells and innate-like T cells after autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"12","author":"Ruder","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319446","article-title":"Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis","volume":"90","author":"Moore","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1601223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:30:31Z","timestamp":1751283031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1601223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2025.1601223"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1601223","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1601223"}}